2seventy bio completes $40m haemophilia A program deal with Novo Nordisk
2seventy bio’s deal with Novo Nordisk also includes the rights to its MegaTAL in vivo gene editing technology.
2seventy bio’s deal with Novo Nordisk also includes the rights to its MegaTAL in vivo gene editing technology.
The collaboration is intended to leverage OpenAI's generative AI-based platform to invent novel antimicrobials to treat drug-resistant pathogens.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine
Ability Biologics closes extended $18m seed funding round
The lasting impacts of the pandemic on cybersecurity in healthcare
Q&A with Springer Nature’s Leslie Lansman: Ethical content sharing and the benefits of the CLA Pharmaceutical Licence